The short answer
Senna can contribute to low potassium when it causes diarrhea or is overused. Because adagrasib has heart-rhythm and electrolyte precautions, agree on the laxative dose and duration with your cancer team.
What this answer covers
Oral Senna alexandrina stimulant laxatives with oral adagrasib. The inspected monograph covers defined pod preparations; chronic misuse, bowel cleansing, leaf products and combinations are distinct exposures.
- Supplement or preparation
- Senna alexandrina
- Medication ingredient
- adagrasib
The concern is potassium loss
Senna can cause diarrhea, and prolonged laxative misuse can disturb fluid and electrolyte balance, including potassium. Krazati labeling also reports low potassium and requires correction of electrolyte abnormalities when indicated. These overlapping concerns are most relevant with diarrhea, excessive use or other risk factors.
Low potassium can add to heart-rhythm risk
Adagrasib can prolong the QT interval. Potassium and magnesium abnormalities matter when clinicians assess that risk. This does not mean senna has been shown to directly prolong QT with adagrasib, or that the risk of every short course is known.
Ask for a constipation plan
The senna monograph describes short-term use and advises review when a laxative is needed daily. Do not keep increasing doses for persistent constipation or take it for unexplained abdominal pain, nausea or vomiting without advice. Krazati can cause serious digestive problems that need assessment.
Spacing does not prevent ongoing losses
Taking the products a few hours apart has not been shown to prevent potassium loss. Report persistent diarrhea, and seek prompt care for fainting or a fast or irregular heartbeat. The care team should decide about electrolyte checks and replacement; extra potassium tablets are not a substitute for that assessment.
Evidence and practical considerations
Side effects & toxicity
Senna-related diarrhea or prolonged laxative misuse can lower potassium, which is a concern during adagrasib treatment.
- Exact scope
- Oral Senna alexandrina stimulant laxatives with oral adagrasib. The inspected monograph covers defined pod preparations; chronic misuse, bowel cleansing, leaf products and combinations are distinct exposures. with Exact adagrasib RxCUI 2625882 IN, confirmed by current RxNorm properties. Oral Krazati tablets; the August 2026 U.S. label covers single-agent treatment of specified previously treated KRAS G12C-mutated NSCLC. Older cetuximab combination cohorts and regional label instructions are not interchangeable.
- Medication form and route
- Oral
What remains uncertain
- Preparation-specific regulatory warning plus exact drug electrolyte/QT guidance, not a measured exact-pair incidence. A short recommended course is not equivalent to prolonged misuse; senna is not claimed to directly prolong QT.
Factors that may matter: Exact preparation and dose; Treatment phase and duration; Liver function; Electrolyte results and GI symptoms; Other medicines.
Read the supporting source summaries
Source 1: Current U.S. prescribing information
bms.com · Source check Sep 10, 2026
Population: Adults with specified previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Warns about GI toxicity, QT prolongation and hepatotoxicity. Monitor/correct electrolytes, particularly potassium and magnesium, and monitor liver tests. Strong CYP3A inducers lower exposure. Avoid strong CYP3A inhibitors until steady state, approximately eight days. High-fat meal did not meaningfully change exposure; tablets may be taken with or without food.
How this applies: Exact current U.S. guidance; newer than the retained March 2026 DailyMed version. Exact adagrasib RxCUI 2625882 IN, confirmed by current RxNorm properties. Oral Krazati tablets; the August 2026 U.S. label covers single-agent treatment of specified previously treated KRAS G12C-mutated NSCLC. Older cetuximab combination cohorts and regional label instructions are not interchangeable.
Not direct evidence of each botanical combination. Strong-inhibitor effects after a single dose differ from steady-state model predictions. Effects of adagrasib on other CYP substrates are a separate direction. No universal supplement prescription.
Source 2: Final regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of specified senna pod preparations.
Prolonged laxative abuse may cause hypokalemia and electrolyte imbalance. Warns about concomitant QT-prolonging medicines and states that daily laxative need or unexplained abdominal symptoms warrant assessment.
How this applies: Preparation-specific potassium-loss warning combined with the exact adagrasib QT/electrolyte guidance.
No adagrasib study. Pod preparations are not all leaves, teas or combinations; a brief recommended course is not equivalent to chronic misuse or bowel-cleansing exposure.
Source 3: Authoritative medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Medication terminology.
Identifies adagrasib as IN.
How this applies: Exact identity confirmation.
Not clinical interaction evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 5593351a85826dee
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.